Ann Goebel-Fabbri, PhD, a clinical psychologist in Boston, Massachusettes, outlines trends in eating disorders among patients with type 1 diabetes.
Women with type 1 diabetes (T1D) are 2.5 times more likely to develop an eating disorder than their same-age peers, said Ann Goebel-Fabbri, PhD, a clinical psychologist practicing in Boston, Massachusettes. Goebel-Fabbri's talk, "Practical Approaches for Eating Disorders in Diabetes," was presented at this year's American Diabetes Association 81st Scientific Sessions.
Transcript
Can you introduce yourself and describe your work?
My name is Ann Goebel-Fabbri, PhD, and I'm a psychologist here in the Boston area. I worked at Joslin Diabetes Center as a clinical psychologist for about 16 years before going out into private practice, which I've been doing for about 5 or 6 years at this point. Many of my patients are people with diabetes, both type 1 diabetes and type 2 diabetes.
What is the prevalence of eating disorders among those with diabetes? Are there any age- or gender-specific trends?
In terms of gender, the majority of research on eating disorders tends to focus on women. But what we're starting to see is that for certain eating disorders, namely binge eating disorder, there seems to be an equal prevalence among men and women. It's not really clear if maybe anorexia and bulimia are underreported in men or if they truly just do happen at lower prevalence rates. We're not quite sure.
But once you add diabetes to the mix, type 1 diabetes, for example, increases the risk of a woman having an eating disorder by about 2.5 times. So women with type 1 are about 2.5 times more likely to develop an eating disorder of any kind than their same-age peers. It seems from the literature as though they tend to get diagnosed a little bit later than we typically think of in terms of eating disorder trends. Typically, the sort of average stereotype is of an adolescent girl with an eating disorder, and in type 1 diabetes, the early 20s seems to be when women are more likely to be diagnosed.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More